Skip to main content

Animations

MJFF Publications

6501 - 6510 of 6516 Results
Title
Year
  • Year
  • 2021
  • 2025
  • 2009
  • 2023
  • 2009
  • 2023
  • 2022
  • 2009
  • 2008
  • 2003
  • Summary Details
    OPEN
    Title: Open science takes on Parkinson’s disease
    Journal Name: eLife
    Publisher: eLife Sciences Publications, Ltd
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.7554/elife.66546
    Citation Count: 27
  • Summary Details
    OPEN
    Title: Type II kinase inhibitors that target Parkinson’s disease–associated LRRK2
    Journal Name: Science Advances
    Publisher: American Association for the Advancement of Science (AAAS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1126/sciadv.adt2050
    Citation Count: 14
  • Summary Details
    OPEN
    Title: Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson’s disease models
    Journal Name: Disease Models & Mechanisms
    Publisher: The Company of Biologists
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1242/dmm.004267
    Citation Count: 175
  • Summary Details
    OPEN
    Title: From policy to practice: Lessons learned from an open science funding initiative
    Journal Name: PLOS Computational Biology
    Publisher: Public Library of Science (PLoS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1371/journal.pcbi.1011626
    Citation Count: 4
  • Summary Details
    OPEN
    Title: α-Synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity
    Journal Name: Nature Genetics
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1038/ng.300
    Best OA location URL: http://doi.org/10.1038/ng.300
    Citation Count: 536
  • Summary Details
    OPEN
    Title: LINE-1 retrotransposons drive human neuronal transcriptome complexity and functional diversification
    Journal Name: Science Advances
    Publisher: American Association for the Advancement of Science (AAAS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc, cc-by, cc-by
    DOI - Digital Object Identifier: 10.1126/sciadv.adh9543
    Citation Count: 64
  • Summary Details
    OPEN
    Title: Use of Glycolysis‐Enhancing Drugs and Risk of Parkinson's Disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1002/mds.29184
    Citation Count: 28
  • Summary Details
    OPEN
    Title: Rapid selection of cyclic peptides that reduce α-synuclein toxicity in yeast and animal models
    Journal Name: Nature Chemical Biology
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1038/nchembio.193
    Citation Count: 137
  • Summary Details
    OPEN
    Title: Hsp104 antagonizes α-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease
    Journal Name: Journal of Clinical Investigation
    Publisher: American Society for Clinical Investigation
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1172/jci35781
    Citation Count: 195
  • Summary Details
    OPEN
    Title: Pitx3 is required for development of substantia nigra dopaminergic neurons
    Journal Name: Proceedings of the National Academy of Sciences
    Publisher: Proceedings of the National Academy of Sciences
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1073/pnas.0230529100
    Citation Count: 387
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.